## Drug Summary
Imatinib, marketed under various names including Celonib, Enliven, and Gleevec, is a revolutionary tyrosine kinase inhibitor primarily used in oncology, particularly for the treatment of chronic myeloid leukemia (CML) and gastrointestinal stromal tumors (GIST). It targets the abnormal BCR-ABL fusion protein created by the Philadelphia chromosome, a hallmark of CML. Imatinib has a high oral bioavailability and is absorbed quickly, with peak plasma concentrations reached within 2-4 hours following administration. It is primarily metabolized by the enzyme CYP3A4, with its pharmacokinetics being dose-proportional across a wide range. The drug has been associated with substantial clinical benefits in terms of response rates and overall survival in CML patients.

## Drug Targets, Enzymes, Transporters, and Carriers
Imatinib acts on multiple tyrosine kinases including BCR-ABL, KIT, RET, NTRK1, CSF1R, PDGFRA, DDR1, PDGFRB, and DDR2. This wide range of targets explains its effectiveness against various types of cancers beyond CML, such as GIST, which often harbor c-Kit mutations. The drug is metabolized predominantly by CYP3A4, along with minor involvement from other cytochromes like CYP1A2, CYP2C9, CYP2D6, and CYP2C19. Important transporters involved with imatinib include ABCB1 and ABCG2, which are crucial for drug efflux and could impact drug accumulation and resistance. Imatinib is also known to bind to carriers such as serum albumin (ALB) and alpha-1-acid glycoprotein 1 (ORM1), which could influence its distribution and free fraction in the plasma.

## Pharmacogenetics
The pharmacogenetics of imatinib are primarily centered around its metabolism and transport. Variants in the CYP3A4 gene can significantly affect the metabolism of imatinib, influencing both its efficacy and toxicity profile. For example, CYP3A4*1B and CYP3A5*3 alleles have been linked to altered enzyme activity, potentially requiring dose adjustments. Polymorphisms in the ABCB1 gene, encoding the P-glycoprotein transporter, can affect the pharmacokinetics and resistance to imatinib. Patients with certain ABCB1 variants may experience different drug levels and responses, underscoring the importance of genotyping in the personalized treatment approach. Furthermore, genomic alterations in the target kinases like BCR-ABL and KIT can also dictate responsiveness to imatinib, making genetic testing a valuable tool in managing and optimizing treatment with this drug.